

**THE 6th EXPERT MEETING ON THERAPEUTIC MSCs FOR IMMUNE MODULATION
 REGENSBURG, GERMANY. OCTOBER 27 – 28, 2016**

Thursday 27 October

Meeting Venue

Brücksaal im Historischen Salzstadl
 (directly at the “Steinerne Brücke”)
 Weiße-Lamm-Gasse 1, 93047 Regensburg
 Phone: +49 (0)941 5071415

The “Salzstadel” (salt barn) dates from 1616 and is a reminder of the salt trade from which Regensburg has housed restaurants, several shops and even rentable rooms. The building now also houses the Regensburg UNESCO World Heritage visitor center.



8:30 – onwards registration & view company exhibitions

8:55 MiSOT opening address.
Marc Dahlke, Regensburg, Germany.

Session 1. Mechanistic insights into MSC therapies

- 09:15 What do we really know about MSC therapy?
Martin Hoogduijn, Rotterdam, The Netherlands.
- 09:45 Molecular pathways affected by MSC in a model of non-alcoholic steatohepatitis.
Bruno Christ, Leipzig, Germany
- 10:00 How mechanistic studies on MSCs inform design of human clinical trials - The fitness paradigm.
Jacques Galipeau, Madison, Wisconsin, USA.
- 10:30 Inflammatory conditions dictate the immunomodulatory effect of MSC on B cell function.
Marcella Franquesa, Badalona, Spain.
- 10:45 **Catherine Verfaillie**, Leuven, Belgium.

11:15 Coffee

MiSOT 2016 is generously supported by

TERUMOBCT

MaSTherCell
 Manufacturing Synergies for Therapeutic Cells



OrbsenTherapeutics
 Redefining Cell Therapy

TIGENIX
 Living Medicines
SEPCELL 
STEM CELL THERAPY FOR COMMONLY ACQUIRED IMMUNODEFICIENCY

Athersys
 i n c.

apceth
 applied cell therapy



**BECKMAN
 COULTER**

Session 2. MSC for solid organ transplantation

- 11:35 3D MSCs constructs in models of chronic liver failure.
Murat Shagidulin, Moscow, Russia.
- 11:50 What do we learn from MSC treatment in clinical kidney transplantation?
Marlies Reinders, Leiden, The Netherlands.
- 12:20 MSC after deceased donor liver transplantation: a phase I/II study of the University of Liege.
Olivier Detry, Liège, Belgium.
- 12:50 Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation.
Steffen Hartleif, Tübingen, Germany.
- 13:05 Mesenchymal stromal cells to promote tolerance in kidney transplantation: from mice to men and back.
Giuseppe Remuzzi, Bergamo, Italy.

13:35 Lunch

Session 3. MSC for inflammatory and immunological disorders

- 14:35 Cellular Immunotherapy for Severe Sepsis: the CISS Trial.
Claudia Dos Santos, Ottawa, Canada.
- 15:05 **Katarina Le Blanc**, Stockholm, Sweden.
- 15:35 MSC: a new route in the road map of therapies for inflammatory bowel diseases.
Rachele Ciccocioppo, Pavia, Italy.
- 16:05 UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells.
Marta Monguió-Tortajada, Badalona, Spain.
- 16:20 Harnessing Mesenchymal Stromal Cells for Immune Modulatory Treatment.
Wim Fibbe, Leiden, The Netherlands.

19:00 Networking Dinner

Haus Heuport
Domplatz 7, 93047 Regensburg
Phone: +49 (0)941 599 9297
www.heuport.de



MiSOT 2016 is generously supported by

TERUMOBCT

MaSTherCell
Manufacturing Synergies for Therapeutic Cells



OrbsenTherapeutics
Redefining Cell Therapy

TIGENIX
Living Medicines
SEPCELL

Athersys
i n c.

apceth
applied cell therapy



**BECKMAN
COULTER**

Friday 28 October

Session 4. Corporate Session: Bringing MSC-based technologies to market

- 9:00 Generation of polyclonal Tregs with superior expansion potential and enhanced Th1 suppression via MAPC co-culture.
Samantha Stubblefield, Regenerative Medicine Scientist, **Athersys Inc.**
- 9:20 From CD362 to ORBCEL: the rapid development of an allogeneic stromal cell immunotherapy
Stephen Elliman, CSO, **Orbsen Therapeutics.**
- 9:40 Case Study review on large scale manufacturing of MSCs.
Amel Tounsi, Project & Development Manager, **MaSTherCell.**
- 10:00 Potential use of adipose mesenchymal stem cells in sepsis: The SEPCELL trial
Eleuterio Lombardo, Scientific Director, **TiGenix SAU.**
- 10:20 Addressing Challenges in ATMP Manufacture.
Layka Abbasi, Cell processing Specialist, Terumo BCT.
- 10:40 Alpha 1 anti-trypsin expressing mesenchymal stem cells suppress type 1 diabetes development in NOD mice
Felix Hermann, Head of Preclinical Development, **apceth GmbH.**

11:00 Coffee

Session 5. MSC for tissue protection

- 11:15 Impact of timing administration of mesenchymal stromal cells following renal ischemia/reperfusion in rats.
Pauline Erpicum, Liège, Belgium.
- 11:45 MSC in immune-mediated liver disease.
Philip Newsome, Birmingham, UK.
- 12:15 Normothermic Organ Perfusion: Opportunities and Challenges.
Rutger Ploeg, Oxford, UK.
- 12:45 Administering MSCs to an isolated organ prior to transplantation.
Cyril Moers, Groningen, The Netherlands.

13:15 – Lunch plus closing remarks

MiSOT 2016 is generously supported by

TERUMOBCT

MaSTherCell
Manufacturing Synergies for Therapeutic Cells



Orbsen Therapeutics
Redefining Cell Therapy

TiGenix
Living Medicines
SEPCELL



apceth
applied cell therapy



**BECKMAN
COULTER**